Meibomian Gland Dysfunction Global Market Report 2025

The meibomian gland dysfunction market size has grown strongly in recent years. It will grow from $4.13 billion in 2024 to $4.42 billion in 2025 at a compound annual growth rate (CAGR) of 7%. The growth in the historic period can be attributed to greater awareness of dry eye disorders, a rising aging population, increased screen time across all age groups, a growing prevalence of lifestyle-related eye conditions, and a higher incidence of allergic reactions and environmental irritants.

The meibomian gland dysfunction market size is expected to see strong growth in the next few years. It will grow to $5.74 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to the rising adoption of digital lifestyles following the pandemic, an increasing incidence of contact lens-related complications, a growing preference for minimally invasive eye treatments, wider use of thermal pulsation therapies, and an enhanced focus on personalized eye care. Key trends expected during this period include advancements in meibography imaging technology, the development of non-invasive monitoring tools, the integration of ophthalmic and dermatological care, the use of machine learning for gland assessment, and innovations in lipid-based eye drop formulations.

The increasing incidence of eye diseases is anticipated to drive the expansion of the meibomian gland dysfunction (MGD) market in the coming years. Eye disease encompasses any condition or disorder affecting the eye or visual system, compromising its structure, function, or overall health. The surge in eye disease cases is largely due to heightened screen time and digital eye strain, which lead to symptoms like dryness, blurred vision, and potential long-term retinal damage from extended blue light exposure. Meibomian gland dysfunction exacerbates eye diseases by destabilizing the tear film, causing inflammation, dryness, and elevating the risk of ocular surface disorders. For example, in September 2023, a report from the Association of Optometrists, a UK-based representative membership body, revealed that in 2022, England recorded 22,552 new certifications for vision impairment. Among these, 1,344 cases were due to diabetic eye disease, 3,614 were linked to glaucoma, and 10,865 were caused by age-related macular degeneration. Thus, the growing number of eye disease cases is fueling the growth of the meibomian gland dysfunction (MGD) market.

Leading companies in the meibomian gland dysfunction market are concentrating on the development of innovative treatments, such as prescription eye drop solutions, aimed at minimizing tear evaporation and alleviating dry eye symptoms. These prescription drops, including anti-inflammatory or antibiotic formulations, aid in managing meibomian gland dysfunction by reducing inflammation, clearing gland obstructions, and enhancing tear film stability. For example, in May 2023, Bausch + Lomb Corporation, a Canada-based eye care company, launched MIEBO (perfluorohexyloctane ophthalmic solution), an advanced prescription eye drop designed to treat dry eye disease (DED). MIEBO is the first and only prescription drop specifically formulated to target tear evaporation, the primary cause of DED. It creates a long-lasting, protective layer on the eye’s surface. This innovative, water-free formula offers effective and sustained relief, especially for individuals experiencing dry eye symptoms linked to meibomian gland dysfunction.

In July 2023, CS Pharmaceuticals Limited, a pharmaceutical company based in the UK, acquired AxeroVision Inc. for an undisclosed sum. Through this acquisition, CS Pharmaceuticals intends to enhance its ophthalmology portfolio and advance the development of novel therapies for dry eye disease associated with meibomian gland dysfunction (MGD), targeting a significant unmet medical need. AxeroVision Inc. is a biotechnology company based in the US that specializes in creating innovative treatments for meibomian gland dysfunction.

Major players in the meibomian gland dysfunction market are Johnson And Johnson, Alcon Inc., Cleveland Clinic Foundation, Bausch + Lomb Corporation, Santen Pharmaceutical, Lumenis Ltd, Topcon Healthcare Solutions Inc., AFT Pharmaceuticals, Sight Sciences Inc., OASIS Medical Inc., OCuSOFT Inc., Novaliq GmbH, Scope Ophthalmics Ltd, Medmont International Pty Ltd, Azura Ophthalmics Ltd, BlephEx LLC, Bruder Healthcare Company, ESW Vision Inc., MiBo Medical Group Inc., and Kala Pharmaceuticals Inc.

North America was the largest region in the meibomian gland dysfunction market in 2024. The regions covered in meibomian gland dysfunction report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the meibomian gland dysfunction market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Meibomian gland dysfunction (MGD) is a prevalent eye condition characterized by blocked or improperly functioning meibomian glands in the eyelids, which results in poor-quality oil production. This disruption in the tear film leads to symptoms such as dryness, irritation, inflammation, and blurred vision. MGD is a primary contributor to dry eye disease and can vary in severity from mild to severe.

The primary treatment options for MGD include medication, surgery, and lifestyle modifications. Medication involves the use of drugs or therapeutic substances under medical supervision to treat, manage, or prevent the condition. MGD can be classified into obstructive, evaporative, or mixed types based on the nature of the dysfunction. The severity is typically categorized as mild, moderate, or severe. Treatments are distributed through various channels, including hospitals, clinics, pharmacies, and online platforms, and are designed to serve end users such as hospitals, ophthalmology clinics, and home care environments.

The meibomian gland dysfunction market research report is one of a series of new reports that cover meibomian gland dysfunction market statistics, including the meibomian gland dysfunction industry's global market size, regional shares, competitors with the meibomian gland dysfunction market share, detailed meibomian gland dysfunction market segments, market trends and opportunities, and any further data you may need to thrive in the meibomian gland dysfunction market. This meibomian gland dysfunction market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The meibomian gland dysfunction market consists of revenues earned by entities by providing services such as diagnostic services, customized dry eye management plans, and thermal pulsation treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. The meibomian gland dysfunction market also includes sales of artificial tears and lubricating eye drops, omega-3 supplements, prescription medications, and intense pulsed light (IPL) therapy devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.